Speakers

Confirmed speakers

  Andrea Cox, M.D., Ph.D.

B.A., Ph.D. – University of Virginia
M.D. – Johns Hopkins University

Professor of Medicine and Oncology
Director, JHU Medical Scientist (MD-PhD) Training Program
Division of Infectious Diseases Department of Medicine, The Johns Hopkins University School of Medicine
Rangos Research Bldg., Suite 536
855 N. Wolfe St.
Baltimore, Maryland 21205.

Read bio here!

 Steven Deeks, MD

Professor, University of California San Francisco

Steven G. Deeks, MD, is a Professor of Medicine in Residence at the University of California, San Francisco (UCSF) and a faculty member in the Division of HIV, Infectious Diseases and Global Medicine at Zuckerberg San Francisco General Hospital. He is an internationally recognized expert on HIV pathogenesis and treatment. He is also now leading a large program focused on the pathogenesis and treatment of Long COVID.

Read bio here!

  Jordan Feld, MD, MPH

University of Toronto
Dr. Feld trained in GI and Hepatology at the University of Toronto and did post-doctoral training in the Liver Diseases Branch at the National Institutes of Health in laboratory and clinical research in viral hepatitis.  After completing a Masters in Public Health at the Johns Hopkins Bloomberg School of Public Health, he returned to Toronto where holds the R. Phelan Chair in Translational Liver Research as a clinician-scientist at the Toronto Centre for Liver Disease in the Toronto General Hospital where he now leads a large clinical and translational research program focused primarily on viral hepatitis.
Read bio here!

  Johan Neyts, Prof.

University of Leuven, Belgium
Johan Neyts (CV) is full professor of Virology at the University of Leuven (KU Leuven), Belgium where he teaches virology at the medical school and at the school of dentistry. His laboratory of Virology and Antiviral Research has a long-standing expertise in the development of antiviral strategies and drugs against emerging and neglected viral infections such as dengue and other flaviviruses, Chikungunya and other alphaviruses, enteroviruses, noroviruses, HDV, HEV, rabies and coronaviruses. An ultrapotent pan-serotype dengue inhibitor developed in his laboratory and at the Centre for Drug Design & Development (CD3) is currently in phase II clinical studies at Johnson & Johnson and efficacy has recently been shown in dengue-infected humans…
Read bio here!

  Raymond F. Schinazi

(honorary doctor at Uppsala University 2025), Emory Univ, Atlanta

Raymond F. Schinazi (born 21 March 1950) is an Egyptian organic medicinal chemist. He is the Frances Winship Walters Professor of Pediatrics at Emory University. He has expertise in antiviral agents, pharmacology, and biotechnology. His research focuses on developing treatments for infections caused by human immunodeficiency virus (HIV), hepatitis B (HBV), hepatitis C (HCV), herpes, dengue fever, zika, chikungunya, and other emerging viruses. These treatment options include antiviral agents as well as synthetic, biochemical, pharmacological and molecular genetic approaches, including molecular modeling and gene therapy.

Read bio here!

  Dr. Stephan Urban

University of Heidelberg
German Center for Infection Research (DZIF) – Heidelberg Partner Site, Heidelberg, Germany

Professor Stephan Urban is head of the Translational Virology unit at the Department of Infectious Diseases, Molecular Virology at Heidelberg University Hospital. Between 2008 and 2012 he was Project coordinator of the BMBF-network “Innovative Therapies” and is now coordinating the Hepatitis D project within the German Center for Infection Research (DZIF) TTU Hepatitis.

Read bio here!

  Annemarie M.J. Wensing, MD, PhD

University Medical Center Utrecht

Annemarie M.J. Wensing, MD, PhD is a Clinical Virologist at the University Medical Center Utrecht and a Honorary Professor at the University of the Witwatersrand in Johannesburg.

She attained her MSc and MD at the University of Utrecht. During her post graduate rotations she became involved in clinical HIV research and care. She worked at the HIV outpatient clinic of the University Medical Center (UMC) Utrecht and was subsequently trained as a clinical virologist. She obtained her PhD on Transmission of drug resistant HIV-1. Her research focuses on improving antiviral treatment and viral eradication strategies globally by integrating insights from clinical and fundamental research on drug resistance, viral persistence, and evolution…

Read bio here!

Chairmen

  • Josef Järhult
  • Johan Lennerstrand
  • Magnus Lindh
  • Piotr Nowak
  • Matti Sällberg
  • Nina Weis

Head organizer

  • Johan Lennerstrand